D
Kiniksa Pharmaceuticals International, plc
KNSA
$20.37
-$1.39-6.39%
D
Sell
2/27/2025Upgraded
Kiniksa Pharmaceuticals International, plc (KNSA) was upgraded to D+ from D- on 2/27/2025 due to a significant increase in the efficiency index and valuation index. Net income increased 29.98% from -$12.69M to -$8.89M, and total capital increased 0.15% from $447.6M to $448.29M.
Kiniksa Pharmaceuticals International, plc (KNSA) was upgraded to D+ from D- on 2/27/2025 due to a significant increase in the efficiency index and valuation index. Net income increased 29.98% from -$12.69M to -$8.89M, and total capital increased 0.15% from $447.6M to $448.29M.
D
Sell
10/31/2024Downgrade
Kiniksa Pharmaceuticals International, plc (KNSA) was downgraded to D- from D+ on 10/31/2024 due to a large decline in the efficiency index and valuation index. Net income declined 224.8% from -$3.91M to -$12.69M.
Kiniksa Pharmaceuticals International, plc (KNSA) was downgraded to D- from D+ on 10/31/2024 due to a large decline in the efficiency index and valuation index. Net income declined 224.8% from -$3.91M to -$12.69M.
D
Sell
8/15/2024Upgraded
Kiniksa Pharmaceuticals International, plc (KNSA) was upgraded to D+ from D on 8/15/2024 due to a large increase in the total return index and volatility index.
Kiniksa Pharmaceuticals International, plc (KNSA) was upgraded to D+ from D on 8/15/2024 due to a large increase in the total return index and volatility index.
D
Sell
7/29/2024Downgrade
Kiniksa Pharmaceuticals International, plc (KNSA) was downgraded to D from D+ on 7/29/2024 due to a decline in the valuation index and efficiency index.
Kiniksa Pharmaceuticals International, plc (KNSA) was downgraded to D from D+ on 7/29/2024 due to a decline in the valuation index and efficiency index.
D
Sell
7/22/2024Upgraded
Kiniksa Pharmaceuticals International, plc (KNSA) was upgraded to D+ from D on 7/22/2024 due to an increase in the total return index and volatility index.
Kiniksa Pharmaceuticals International, plc (KNSA) was upgraded to D+ from D on 7/22/2024 due to an increase in the total return index and volatility index.
D
Sell
6/12/2024Downgrade
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to D from D+ on 6/12/2024 due to a decline in the total return index and volatility index.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to D from D+ on 6/12/2024 due to a decline in the total return index and volatility index.
D
Sell
5/28/2024Upgraded
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to D+ from D on 5/28/2024 due to a noticeable increase in the total return index.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to D+ from D on 5/28/2024 due to a noticeable increase in the total return index.
D
Sell
4/26/2024Downgrade
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to D from D+ on 4/26/2024 due to a decline in the growth index, total return index and valuation index. EBIT declined 20,522.22% from $81 to -$16.54M, earnings per share declined from $0.352 to -$0.2506, and operating cash flow declined 7.82% from $4.33M to $3.99M.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to D from D+ on 4/26/2024 due to a decline in the growth index, total return index and valuation index. EBIT declined 20,522.22% from $81 to -$16.54M, earnings per share declined from $0.352 to -$0.2506, and operating cash flow declined 7.82% from $4.33M to $3.99M.
D
Sell
2/29/2024Upgraded
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to D+ from D on 2/29/2024 due to a noticeable increase in the growth index, total return index and efficiency index. Net income increased 282.15% from -$13.86M to $25.24M, earnings per share increased from -$0.2 to $0.352, and EBIT increased 100.74% from -$10.93M to $81.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to D+ from D on 2/29/2024 due to a noticeable increase in the growth index, total return index and efficiency index. Net income increased 282.15% from -$13.86M to $25.24M, earnings per share increased from -$0.2 to $0.352, and EBIT increased 100.74% from -$10.93M to $81.
D
Sell
11/3/2023Downgrade
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to D from C on 11/3/2023 due to a significant decline in the valuation index, growth index and efficiency index. EBIT declined 246.45% from -$3.15M to -$10.93M, earnings per share declined from $0.21 to -$0.2, and net income declined 192.54% from $14.97M to -$13.86M.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to D from C on 11/3/2023 due to a significant decline in the valuation index, growth index and efficiency index. EBIT declined 246.45% from -$3.15M to -$10.93M, earnings per share declined from $0.21 to -$0.2, and net income declined 192.54% from $14.97M to -$13.86M.
C
Hold
8/2/2023Upgraded
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to C from D+ on 8/2/2023 due to a significant increase in the growth index, solvency index and total return index. Earnings per share increased from -$0.18 to $0.21, EBIT increased 71.83% from -$11.2M to -$3.15M, and total revenue increased 47.84% from $48.35M to $71.47M.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to C from D+ on 8/2/2023 due to a significant increase in the growth index, solvency index and total return index. Earnings per share increased from -$0.18 to $0.21, EBIT increased 71.83% from -$11.2M to -$3.15M, and total revenue increased 47.84% from $48.35M to $71.47M.
D
Sell
7/25/2023Upgraded
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to D+ from D on 7/25/2023 due to an increase in the volatility index and total return index.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to D+ from D on 7/25/2023 due to an increase in the volatility index and total return index.
D
Sell
3/30/2023Downgrade
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to D from D+ on 3/30/2023 due to a decline in the volatility index and total return index.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to D from D+ on 3/30/2023 due to a decline in the volatility index and total return index.
D
Sell
3/3/2023Downgrade
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to D+ from C- on 3/3/2023 due to a substantial decline in the growth index, total return index and efficiency index. Operating cash flow declined 118.66% from $62.05M to -$11.58M, earnings per share declined from $3.18 to $0.0542, and net income declined 98.01% from $224.09M to $4.46M.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to D+ from C- on 3/3/2023 due to a substantial decline in the growth index, total return index and efficiency index. Operating cash flow declined 118.66% from $62.05M to -$11.58M, earnings per share declined from $3.18 to $0.0542, and net income declined 98.01% from $224.09M to $4.46M.
C
Hold
2/9/2023Downgrade
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to C- from C on 2/9/2023 due to a noticeable decline in the total return index and valuation index.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to C- from C on 2/9/2023 due to a noticeable decline in the total return index and valuation index.
C
Hold
11/8/2022Upgraded
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to C from C- on 11/8/2022 due to a large increase in the total return index.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to C from C- on 11/8/2022 due to a large increase in the total return index.
C
Hold
11/4/2022Upgraded
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to C- from D on 11/4/2022 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 1,221.53% from -$19.98M to $224.09M, and total capital increased 147.12% from $158.11M to $390.72M.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to C- from D on 11/4/2022 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 1,221.53% from -$19.98M to $224.09M, and total capital increased 147.12% from $158.11M to $390.72M.
D
Sell
5/16/2022Upgraded
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index and valuation index.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index and valuation index.
E
Sell
5/13/2022Downgrade
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to E+ from D on 5/13/2022 due to a noticeable decline in the solvency index, volatility index and total return index. The quick ratio declined from 4.15 to 3.48.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to E+ from D on 5/13/2022 due to a noticeable decline in the solvency index, volatility index and total return index. The quick ratio declined from 4.15 to 3.48.
D
Sell
5/5/2022Upgraded
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index, growth index and solvency index. The quick ratio declined from 5.91 to 4.15, earnings per share declined from -$0.4448 to -$0.5268, and EBIT declined 17.82% from -$30.67M to -$36.13M.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index, growth index and solvency index. The quick ratio declined from 5.91 to 4.15, earnings per share declined from -$0.4448 to -$0.5268, and EBIT declined 17.82% from -$30.67M to -$36.13M.
D
Sell
11/9/2021Upgraded
Kiniksa Pharmaceuticals International, plc (KNSA) was upgraded to D from E+ on 11/09/2021.
Kiniksa Pharmaceuticals International, plc (KNSA) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index.
D
Sell
5/1/2020Upgraded
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to D from D- on 5/1/2020 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 17.42% from -$29.27M to -$24.17M.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to D from D- on 5/1/2020 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 17.42% from -$29.27M to -$24.17M.
D
Sell
4/15/2019Downgrade
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to D- from D on 4/15/2019 due to a large decline in the efficiency index, growth index and volatility index. Net income declined 74.47% from -$24.41M to -$42.58M, earnings per share declined from -$0.5065 to -$0.8787, and EBIT declined 68.72% from -$26.16M to -$44.14M.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was downgraded to D- from D on 4/15/2019 due to a large decline in the efficiency index, growth index and volatility index. Net income declined 74.47% from -$24.41M to -$42.58M, earnings per share declined from -$0.5065 to -$0.8787, and EBIT declined 68.72% from -$26.16M to -$44.14M.
D
Sell
8/29/2018Upgraded
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to D from E on 8/29/2018 due to an increase in the volatility index and total return index.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to D from E on 8/29/2018 due to an increase in the volatility index and total return index.
E
Sell
8/28/2018Upgraded
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to E from E- on 8/28/2018 due to an increase in the volatility index and total return index.
Kiniksa Pharmaceuticals, Ltd. (KNSA) was upgraded to E from E- on 8/28/2018 due to an increase in the volatility index and total return index.
E
Sell
8/17/2018None
Kiniksa Pharmaceuticals International, plc (KNSA) was downgraded to E- from U on 08/17/2018.
Kiniksa Pharmaceuticals International, plc (KNSA) was downgraded to E- from U on 08/17/2018.
NASDAQ
04/04/2025 12:52PM Eastern
Quotes delayed
